In the VALENTINO phase II trial of non-inferiority, maintenance therapy with 5-FU/leucovorin?+?panitumumab after eight cycles with FOLFOX?+?panitumumab demonstrated superiority to panitumumab monotherapy in PFS [42]
In the VALENTINO phase II trial of non-inferiority, maintenance therapy with 5-FU/leucovorin?+?panitumumab after eight cycles with FOLFOX?+?panitumumab demonstrated superiority to panitumumab monotherapy in PFS [42]. Conversely, experts did not recommend…